MSB 3.21% $1.13 mesoblast limited

Time is coming, page-224

  1. 3,952 Posts.
    lightbulb Created with Sketch. 1352
    Time is coming. Yes I believe so.

    Those that have been waiting in anticipation of development progress with JCR and Temcell for the indication of nHIE that we extended our license agreement way back. Our waiting period may be coming to a end.

    Looks like 13 patients were enrolled in the treatment arms and a follow up study was started in June of last year and completed enrollment in June this year

    Seems likely that the first trial appears to have been positive.

    https://rctportal.niph.go.jp/en/result
    sorry link did not work
    Last edited by Bazsa: 13/09/22
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.